zurück

Trastuzumab deruxtecan (new indication: gastric or gastroesophageal junction (GEJ) adenocarcinoma; HER2-positive; after a trastuzumab-based regimen)

 

Subject:

  • Active Substance: Trastuzumab deruxtecan
  • Name: Enhertu®
  • Therapeutic area: Gastric or gastroesophageal junction (GEJ) adenocarcinoma
  • Pharmaceutical company: Daiichi Sankyo Deutschland GmbH

 

Time table:

  • Start: 01.02.2023
  • Publication of assessment: 02.05.2023
  • End of public hearing: 23.05.2023
  • Final decision by G-BA: middle of July 2023

 

Comparative therapy:

  1. After prior first-line trastuzumab-based first-line therapy:
    Therapy at the physician's discretion (the following treatment options are considered appropriate comparators: Irinotecan, docetaxel, paclitaxel, ramucirumab in combination with paclitaxel)
     
  2. After at least two prior treatment regimens, including trastuzumab:
    Trifluridine / tipiracil